Recommendation of the President – Oxlumo (lumaziran)
On 23 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 20/2025 on the reimbursement of the medicinal product Oxlumo (lumaziran) under the B.129.FM drug program. “Treatment of patients with primary hyperoxaluria type 1 (ICD-10: E74.8)”